Kallyope is exploring the gut-brain axis to discover therapeutics. The gut-brain axis refers to the bi-directional communication between the organs that regulate numerous physiological processes. Many diseases including obesity and diabetes are suspected to be caused by perturbations in the gut-brain axis. By exploring the axis using a systems biology approach and combining the research output with drug discovery expertise, Kallyope is identifying small molecule therapeutics that can restore effective communication. The approach involves Kallyope’s Klarity Platform, an end-to-end process that integrates information from single-cell sequencing, optogenetics, organoids and human genetics with their gut-targeted chemistry of small molecules to build a diverse portfolio of therapies. 

<p>Kallyope is exploring the gut-brain axis to discover therapeutics. The gut-brain axis refers to the bi-directional communication between the organs that regulate numerous physiological processes. Many diseases including obesity and diabetes are suspected to be caused by perturbations in the gut-brain axis. By exploring the axis using a systems biology approach and combining the research output with drug discovery expertise, Kallyope is identifying small molecule therapeutics that can restore effective communication. The approach involves Kallyope’s Klarity Platform, an end-to-end process that integrates information from single-cell sequencing, optogenetics, organoids and human genetics with their gut-targeted chemistry of small molecules to build a diverse portfolio of therapies. </p>


Kallyope

Founded: 2015
Location: New York, NY
Employee range: 50 - 200
Funding: $236M D Feb 2022; $112M C Mar 2020; $21M B Dec 2018; $66M B Feb 2018; $44M A Dec 2015

Short description:

Drug notes:

Long description:

Jobs: